Eli Lilly and Pfizer’s nonopioid NGF inhibitor tanezumab beat out placebo in a phase 3 study of patients with chronic lower back pain.

Aradigm’s bid to get an inhaled antibiotic to market seems at an end, with its assets up for sale and the jobs of two primary executives terminated.

Joe Anderson stepped down as CEO in September to take up the chief investment officer position but now finds himself back in charge of the company.

In a pivotal phase 3 study, Intercept Pharmaceuticals' obeticholic acid improved liver fibrosis without any worsening of NASH after 18 months.

TCR2 Therapeutics has priced its IPO at the midpoint of the target range. The offering stands to net TCR2 $67 million.

A protein originally developed to boost the power of T cells in treating cancer protected normal mice from developing cancer in the first place.

The deal, which was signed into law on Friday by President Trump, includes the biggest increase in FDA funding in several years.

Sanofi's CMO takes on chief digital officer role; Parexel nabs four high-profile FDA staffers; and Nimbus poaches Janssen's discovery head as CSO.